Why the CNS boom owes its success to breakthroughs in neurological pathologies

Summary

Article discusses how the CNS sector has achieved growth through shifts in therapeutic development emphasis from symptom management to biomarker-driven approaches for neurological diseases. No specific companies, drugs, clinical trials, or regulatory catalysts are mentioned.